With over 70 years in the pharma industry and 280 different pharmaceutical products, Rekah is working to increase its international presence by focusing on out-licensing, in-licensing, establishing new partnerships and executing mergers and acquisitions.
We are focusing on adjusting our corticosteroid product line and additional niche products to regulatory requirements abroad.
The international activity of the Rekah Group is carried out in several channels:
Rekah Group's export activity is focused on the ophthalmologic, steroid and specialty products.
The company develops itself and maintains collaborations to expand the product line and ad-dresses the domestic market and international markets, with an emphasis on the European mar-ket.
The group exports several products to a major market in Europe and the Far East and in registra-tion procedures in markets in Europe, North America, and Asia.
In 2021 the group launched a core product in a central western country and there is registration and registration operations at various stages in other countries in Europe and North America.
The Rekah Group has a diverse portfolio that includes about 300 products and an independent marketing capability that reaches all customers throughout the country.
The group is active in the market of hospitals, health funds and pharmacies and works to register generic products in the field of antibiotics, metabolic diseases, and other products in Israel.
Rekah is looking for international partners to license complementary and synergistic products for its activities in the domestic and international market.
Rekach Group develops itself and is looking for partners for technology transfer and technology absorption and co-developments in the core areas of its activities.
The company is also looking for joint ventures in areas that support the company's strategy and focus on overseas markets.
In 2021, Rekah acquired “Tree of Life”, a company that develops, manufactures, imports, markets and sells innovative medical devices and health products. This is the first strategic and synergistic acquisition of the Rekah Group, which allows it to enter the growing medical device field in Israel and around the world. This acquisition opens the door to a significant growth channel in Israel and abroad by immediate-ly expanding the product portfolio with innovative products in new areas, marketing registration and distribution infrastructure in foreign markets, regulatory capabilities, and development in the field of medical devices. The acquisition of “Tree of Life” strengthens the position of the Rekah Group as a leading pharmaceutical company in Israel.